KANE BIOTECH INC ORD - KNBIF STOCK NEWS

Welcome to our dedicated page for KANE BIOTECH ORD news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on KANE BIOTECH ORD stock.

Kane Biotech Inc. (KNBIF) is a biotechnology company dedicated to researching, developing, and commercializing technologies and products that prevent and eliminate microbial biofilms. With a robust portfolio of intellectual property and products like StrixNB™, DispersinB®, Aledex™, coactiv+™, DermaKB™, and revyve™, the company is at the forefront of biofilm research. Recently, Kane Biotech announced the sale of its interest in STEM Animal Health, entered new licensing and distribution agreements, and received US FDA clearance for its revyve™ Antimicrobial Wound Gel. The company is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.

05/16/2024 08:00 AM

News

Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024

Rhea-AI Summary

Kane Biotech (TSX-V:KNE; OTCQB:KNBIF), a biotechnology firm specializing in microbial biofilm prevention and removal technologies, will disclose its Q1 2024 financial results on May 23, 2024, after market close.

The company’s management will present a corporate update at a Special and Annual General Meeting via videoconference on May 22, 2024, at 5:00pm EST.

Participants can register for the meeting using the provided link.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

05/15/2024 08:00 AM

News

Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map

Rhea-AI Summary

Kane Biotech has announced the commercialization of the Schultz Biofilm Wound Map, a patented in vitro assay dedicated to detecting biofilms in wound beds. This kit, named in honor of the late Dr. Greg Schultz, former Chief Science Officer at Kane Biotech and Professor Emeritus at the University of Florida, marks a significant advancement in wound care by identifying and mapping microbial biofilms. Dr. Schultz, who passed away on April 12, 2024, was instrumental in developing Kane’s coactiv+™ and DispersinB® technologies and the revyve™ Antimicrobial Wound Gel. His contributions have firmly established Kane Biotech as a leader in biofilm solutions.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/16/2024 09:15 AM

News

Kane Biotech to Host Investor Webinar

Rhea-AI Summary

Kane Biotech Inc. announces an investor webinar to discuss the sale of STEM Animal Health, expected to bring in over $13 million CND. The sale is a strategic move to position Kane as a market leader in wound care and dermatological markets, enhancing the company's focus and financial stability for future growth.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/15/2024 09:15 AM

News

Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products

Rhea-AI Summary

Kane Biotech completes the sale of STEM Animal Health to Dechra Veterinary Products for US $8 million, positioning Kane as a market leader in wound care and dermatological markets. The sale is expected to net Kane approximately CND $13 million, allowing for key milestones in commercial launches, global growth, and clinical programs.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/11/2024 09:45 AM

News

Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health

Rhea-AI Summary

Kane Biotech Inc. announces the sale of its interest in STEM Animal Health Inc. to a multi-national pharmaceutical company for US $8,000,000, with additional consideration totaling over CND $11,500,000. The company will use the proceeds to repay its loan and for general working capital purposes, strengthening its balance sheet. The transaction includes a sales-based milestone payment and agreements for product development and transitional manufacturing with STEM.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/26/2024 04:05 PM

News

Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary

Kane Biotech Inc. announces its financial results for Q4 and full year 2023, revealing a non-binding offer for its interest in STEM Animal Health. The company received deposits totaling US $1.525 million towards the sale. Q4 saw positive revenue growth with an increase in license and royalty income by 66%, product revenue by 9%, and total revenue by 11%. However, operating expenses surged by 96%, leading to a loss of ($1,611,894) for the quarter. Full year 2023 showed a decrease in license and royalty income by 22% but an increase in product revenue by 25%. Despite a 6% rise in total revenue, the company reported a higher loss of ($5,270,053) for the year.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/20/2024 08:30 AM

News

Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

Rhea-AI Summary

Kane Biotech Inc. extends the exclusivity period for its interest in STEM Animal Health until March 31, 2024. The company has received additional deposits totaling US $900,000 towards the sale price.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/19/2024 04:10 PM

News

Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow

Rhea-AI Summary

Kane Biotech Inc. to announce Q4 and full year 2023 financial results on March 26, 2024. Conference call to discuss results and business developments.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/08/2024 09:00 AM

News

Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award

Rhea-AI Summary

Kane Biotech Inc. receives the BAM Company of the Year award for its significant achievements in 2023, including FDA clearance, distribution agreements, licensing agreements, and revenue growth.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/22/2024 08:00 AM

News

Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair

Rhea-AI Summary

Kane Biotech Inc. appoints Dr. Robert Huizinga as a director and Executive Chair, focusing on strategic initiatives and partnerships to enhance wound and skin care solutions. Dr. Huizinga's background in Nephrology and successful FDA approval history brings valuable expertise to Kane Biotech.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of KANE BIOTECH ORD (KNBIF)?

The current stock price of KANE BIOTECH ORD (KNBIF) is $0.0767 as of November 22, 2024.

What is the market cap of KANE BIOTECH ORD (KNBIF)?

The market cap of KANE BIOTECH ORD (KNBIF) is approximately 10.2M.

What is Kane Biotech Inc. known for?

Kane Biotech is recognized for its research, development, and commercialization of technologies and products that prevent and remove microbial biofilms.

What are some of the key products offered by Kane Biotech?

Some of the key products offered by Kane Biotech include StrixNB™, DispersinB®, Aledex™, coactiv+™, DermaKB™, and revyve™.

Where is Kane Biotech listed?

Kane Biotech is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.

What recent achievements has Kane Biotech announced?

Kane Biotech recently announced the sale of its interest in STEM Animal Health, entered new licensing and distribution agreements, and received US FDA clearance for its revyve™ Antimicrobial Wound Gel.

Who is the President and CEO of Kane Biotech?

The President and CEO of Kane Biotech is Marc Edwards.

What sets Kane Biotech apart in the biotechnology industry?

Kane Biotech stands out for its focus on biofilm research and its innovative portfolio of intellectual property and products.

How can investors participate in Kane Biotech's growth?

Investors can engage with Kane Biotech by trading its shares on the TSX Venture Exchange under the symbol 'KNE' or on the OTCQB Venture Market under the symbol 'KNBIF'.